‘Hopeful technology’ could change detection, diagnosis of deadly ovarian cancer

‘Hopeful technology’ could change detection, diagnosis of deadly ovarian cancer

Ovarian cancer claims the lives of more than 14,000 women in the U.S. each year, ranking fifth among cancer deaths in women. A multidisciplinary team at Washington University has found an innovative way to use sound and light to diagnose ovarian tumors, which may lead to a promising new diagnostic imaging technique to improve current standard of care.
Focused delivery for brain cancers

Focused delivery for brain cancers

Hong Chen, assistant professor of biomedical engineering in the School of Engineering & Applied Science and assistant professor of radiation oncology at the School of Medicine, reached across disciplines to work toward a more focused drug delivery system that could target tumors lodged in the brainstem, the body’s most precious system.
Battling cancer on two wheels

Battling cancer on two wheels

With a PhD in business, you might not expect Chris Boerner, AB ’93,  to be fighting cancer. Yet as head of international markets at Bristol-Myers Squibb, he works to bring life-saving immuno-oncology cancer drugs to international markets. In his free time, Boerner participates in two bike rides that raise more than $1 million annually for cancer research.

Discovery helps show how breast cancer spreads

School of Medicine researchers have discovered why breast cancer patients with dense breasts are more likely than others to develop aggressive tumors that spread. The finding opens the door to drug treatments that prevent metastasis. Shown are collagen fibers at the boundary of a tumor. Fibers that tend to be perpendicular to the tumor’s surface indicate a poor prognosis.

PSA test better predicts cancer in men taking prostate-shrinking drug

A new study by Gerald Andriole, MD, chief of urologic surgery at Washington University School of Medicine in St. Louis, suggests the PSA test is more reliable in men taking dutasteride (Avodart®), a drug widely prescribed to shrink an enlarged prostate gland. Even a slight rise in PSA levels among men taking the drug was a stronger indicator of cancer than rising PSA levels in men taking a dummy pill.